Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity.

Mistarz A, Komorowski MP, Graczyk MA, Gil M, Jiang A, Opyrchal M, Rokita H, Odunsi KO, Kozbor D.

Mol Ther Oncolytics. 2019 Jul 3;14:233-245. doi: 10.1016/j.omto.2019.06.003. eCollection 2019 Sep 27.

2.

Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.

Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.

Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545. [Epub ahead of print]

PMID:
31265121
3.

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.

Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.

PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.

4.

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.

Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D.

Mol Ther Oncolytics. 2016 Dec 14;3:16034. doi: 10.1038/mto.2016.34. eCollection 2016.

5.

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2016 Oct;26(8):1440-7. doi: 10.1097/IGC.0000000000000785.

6.

Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry.

Brightwell RM, Grzankowski KS, Kaur J, Poblete S, Miller A, Lele SB, Sucheston-Campbell L, Moysich K, Odunsi KO.

Am J Clin Exp Obstet Gynecol. 2015;2(1):39-44. Epub 2015 Feb 15.

7.

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer.

Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, Cannioto RA, Lele SB, Odunsi KO, Moysich KB.

J Low Genit Tract Dis. 2015 Jul;19(3):189-93. doi: 10.1097/LGT.0000000000000104.

8.

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Kolomeyevskaya NV, Lele SB, Miller A, Riebandt GC, Blum BL, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2015 Jan;25(1):42-8. doi: 10.1097/IGC.0000000000000307.

9.

CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.

Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, Odunsi KO, Kozbor D.

J Immunol. 2014 Nov 15;193(10):5327-37. doi: 10.4049/jimmunol.1400201. Epub 2014 Oct 15.

10.

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL; OCGN, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P; SWE-BRCA, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FB; HEBON, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE; EMBRACE, Bove B, Godwin AK, Stoppa-Lyonnet D; GEMO Study Collaborators, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.

11.

Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

Pejovic T, Pande NT, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S, Dim D, Andrews C, Beck A, Tarumi Y, Djilas J, Cappuccini F, Caballero O, Huang J, Levy S, Tsiamouri A, Cain J, Bagby GC, Strausberg RL, Simpson AJ, Odunsi KO.

Transl Oncol. 2009 Dec;2(4):341-9.

12.

The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer.

Odunsi KO, Lele S, Ghamande S, Seago P, Driscoll DL.

Eur J Gynaecol Oncol. 2001;22(5):325-30.

PMID:
11766731
13.
14.

Serous adenocarcinoma of the uterus presenting as paraneoplastic cerebellar degeneration.

Johns JB, Odunsi KO, Fleischman S, Azodi M, Schwartz PE.

Gynecol Oncol. 1999 May;73(2):326-30.

PMID:
10329056
15.

Necrosis of myometrial choriocarcinoma with fulminating sepsis complicating chemotherapy for trophoblastic tumor.

Odunsi KO, Peck LL, Kohorn EI, Parkash V, Cracchiolo B, Chambers JT, Taylor KJ.

Gynecol Oncol. 1998 Jul;70(1):100-4.

PMID:
9698483
16.

Evidence-based medicine: how do we find the evidence?

Odunsi KO, Cooke IE, Olive DL.

J Am Assoc Gynecol Laparosc. 1998 Aug;5(3):313-8.

PMID:
9668158
17.

The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer.

Odunsi KO, Ganesan TS.

Clin Oncol (R Coll Radiol). 1997;9(1):4-13. Review. No abstract available.

PMID:
9039807

Supplemental Content

Loading ...
Support Center